Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women.

Epperson CN, Pittman B, Czarkowski KA, Bradley J, Quinlan DM, Brown TE.

Menopause. 2011 May;18(5):542-8. doi: 10.1097/gme.0b013e3181fcafd6.

PMID:
21293309
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):97-110. doi: 10.1089/cap.2009.0111. Epub 2011 Apr 13.

PMID:
21488751
[PubMed - indexed for MEDLINE]
3.

Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.

Chamberlain SR, Del Campo N, Dowson J, Müller U, Clark L, Robbins TW, Sahakian BJ.

Biol Psychiatry. 2007 Nov 1;62(9):977-84. Epub 2007 Jul 17.

PMID:
17644072
[PubMed - indexed for MEDLINE]
4.

A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.

Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK.

Int J Neuropsychopharmacol. 2013 Oct;16(9):1959-73. doi: 10.1017/S1461145713000357. Epub 2013 May 14.

PMID:
23672818
[PubMed - indexed for MEDLINE]
5.

Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.

Brown TE, Brams M, Gao J, Gasior M, Childress A.

Postgrad Med. 2010 Sep;122(5):7-17. doi: 10.3810/pgm.2010.09.2196.

PMID:
20861583
[PubMed - indexed for MEDLINE]
6.

Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.

Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C; 31001074-ATT2001 Study Investigators.

CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.

PMID:
22519922
[PubMed - indexed for MEDLINE]
7.

Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.

Wehmeier PM, Schacht A, Ulberstad F, Lehmann M, Schneider-Fresenius C, Lehmkuhl G, Dittmann RW, Banaschewski T.

J Clin Psychopharmacol. 2012 Oct;32(5):653-60.

PMID:
22926599
[PubMed - indexed for MEDLINE]
8.

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T.

Depress Anxiety. 2009;26(3):212-21. doi: 10.1002/da.20549.

PMID:
19194995
[PubMed - indexed for MEDLINE]
9.

Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.

Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, Rubin RL, Pigott TA, Sarkis EH, Fox BK.

J Clin Psychopharmacol. 2013 Feb;33(1):45-54. doi: 10.1097/JCP.0b013e31827d8a23.

PMID:
23277268
[PubMed - indexed for MEDLINE]
10.

Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?

Sumner CR, Haynes VS, Teicher MH, Newcorn JH.

Postgrad Med. 2010 Sep;122(5):52-61. doi: 10.3810/pgm.2010.09.2201.

PMID:
20861588
[PubMed - indexed for MEDLINE]
11.

Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study.

Maziade M, Rouleau N, Lee B, Rogers A, Davis L, Dickson R.

J Child Adolesc Psychopharmacol. 2009 Dec;19(6):709-18. doi: 10.1089/cap.2008.0166.

PMID:
20035589
[PubMed - indexed for MEDLINE]
12.

Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.

Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y.

J Am Acad Child Adolesc Psychiatry. 2006 Oct;45(10):1196-205.

PMID:
17003665
[PubMed - indexed for MEDLINE]
13.

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D.

J Clin Psychopharmacol. 2009 Feb;29(1):44-50. doi: 10.1097/JCP.0b013e318192e4a0.

PMID:
19142107
[PubMed - indexed for MEDLINE]
14.

Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine.

Sobanski E, Sabljic D, Alm B, Dittmann RW, Wehmeier PM, Skopp G, Strohbeck-Kühner P.

Eur Psychiatry. 2013 Aug;28(6):379-85. doi: 10.1016/j.eurpsy.2012.08.001. Epub 2012 Oct 10.

PMID:
23062837
[PubMed - indexed for MEDLINE]
15.

A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD.

Sobanski E, Sabljic D, Alm B, Baehr C, Dittmann RW, Skopp G, Strohbeck-Kuehner P.

Pharmacopsychiatry. 2012 May;45(3):100-7. doi: 10.1055/s-0031-1291319. Epub 2011 Dec 15.

PMID:
22174029
[PubMed - indexed for MEDLINE]
16.

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Simpson D, Plosker GL.

Drugs. 2004;64(2):205-22. Review.

PMID:
14717619
[PubMed - indexed for MEDLINE]
17.

ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.

Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA.

Biol Psychiatry. 2006 Jun 1;59(11):1065-70. Epub 2006 Feb 23.

PMID:
16499880
[PubMed - indexed for MEDLINE]
18.

Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder.

de Jong CG, Van De Voorde S, Roeyers H, Raymaekers R, Allen AJ, Knijff S, Verhelst H, Temmink AH, Smit LM, Rodriques-Pereira R, Vandenberghe D, van Welsen I, ter Schuren L, Al-Hakim M, Amin A, Vlasveld L, Oosterlaan J, Sergeant JA.

J Child Adolesc Psychopharmacol. 2009 Dec;19(6):699-707. doi: 10.1089/cap.2009.0029.

PMID:
20035588
[PubMed - indexed for MEDLINE]
19.

A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.

Tsang TW, Kohn MR, Hermens DF, Clarke SD, Clark CR, Efron D, Cranswick N, Lamb C, Williams LM.

Trials. 2011 Mar 13;12:77. doi: 10.1186/1745-6215-12-77.

PMID:
21396130
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Fast vs. slow switching from stimulants to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder.

Cardo E, Porsdal V, Quail D, Fuentes J, Steer C, Montoya A, Anand E, Escobar R.

J Child Adolesc Psychopharmacol. 2013 May;23(4):252-61. doi: 10.1089/cap.2012.0027.

PMID:
23683140
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk